What the approved label says
The FDA-approved dose for bremelanotide is 1.75 mg administered as a subcutaneous injection, on an as-needed basis, no more than once per 24-hour period and no more than 8 doses per month [9]. The label is specific about timing and frequency, and those constraints are part of what distinguishes the as-needed regimen from a daily medication.
The injection is delivered using a single-dose autoinjector into the abdomen or the thigh. The label instructs that the dose be given at least 45 minutes before anticipated sexual activity [9]. Patients can decide whether the effect was satisfactory and use that judgment to guide future doses, but they cannot exceed one dose in 24 hours or eight doses in a month.
The label also describes when not to use bremelanotide. Contraindications and warnings include uncontrolled hypertension and known cardiovascular disease [9], and the label specifically recommends against concomitant use with oral naltrexone because of a clinically significant pharmacokinetic interaction [10].
This is a summary of the label as published. It is editorial commentary, not medical advice. Anyone considering bremelanotide should review the dosing decision with a qualified prescribing clinician who has evaluated their medical history.
How that dose was chosen
The 1.75 mg dose was not arbitrary. It was selected on the basis of a Phase 2b dose-ranging study that tested three subcutaneous doses — 0.75 mg, 1.25 mg, and 1.75 mg — in premenopausal women with HSDD or female sexual arousal disorder [15]. A responder analysis weighed efficacy across the FSFI-D and FSDS-DAO endpoints against the adverse event profile at each dose.
The 1.75 mg dose produced the largest desire-domain responder rate and the largest reduction in distress, with an adverse event profile that the investigators judged acceptable. That dose then carried forward into the RECONNECT Phase 3 trials [1] and into the FDA-approved label [9].
Earlier Phase 2 work had also evaluated an intranasal formulation [12]. The intranasal formulation produced a measurable subjective desire effect in premenopausal women, but the route was abandoned during development because of post-dose increases in blood pressure that were not acceptable for a chronic as-needed therapy.
Pharmacokinetic profile
The pharmacokinetics of subcutaneous bremelanotide help explain the as-needed regimen. After a 1.75 mg subcutaneous dose:
- Bioavailability by the subcutaneous route is approximately 100% [9].
- Time to peak plasma concentration (Tmax) is approximately 1 hour (range 0.5 to 1.0 hours).
- Peak plasma concentration (Cmax) is approximately 72.8 ng/mL.
- Area under the curve (AUC) is approximately 276 hr*ng/mL.
- Plasma protein binding is approximately 21%.
- Terminal half-life is approximately 2.5 to 2.7 hours (range approximately 1.9 to 4.0 hours).
- Elimination is approximately 64.8% urinary and approximately 22.8% fecal.
The short half-life and rapid Tmax are consistent with an as-needed therapy. By 12 hours after dosing, plasma concentrations have fallen well below peak. This pharmacokinetic shape is also why the label sets a hard limit of one dose per 24 hours: there is no clinical rationale for repeat dosing within that window, and the cardiovascular signal (transient post-dose blood pressure increase) needs time to resolve [8].
Why the as-needed frequency cap matters
The 8-doses-per-month frequency limit is not a generic caution. It reflects two real considerations.
The first is cardiovascular. An ambulatory blood pressure monitoring study in 397 premenopausal women showed transient post-dose increases in systolic blood pressure of 2.4 to 3.2 mmHg versus placebo, peaking within four hours and resolving within twelve hours [8]. In healthy subjects this is small and clinically unimportant. With frequent dosing, those transient elevations stack closer together, and the label is structured to keep them spaced.
The second is pigmentation. Focal hyperpigmentation — localized darkening of skin or mucous membranes, reported in approximately 1% of Phase 3 patients [11] — appears to increase with cumulative dosing frequency. The label's frequency cap is one of the mechanisms intended to limit cumulative MC1R activation and, with it, the risk of pigmentation that may not fully resolve after discontinuation.
Routes that were studied
The approved route is subcutaneous injection via single-dose autoinjector [9]. Two other routes appear in the development record:
- Intranasal. Evaluated in Phase 2 work in premenopausal women with female sexual arousal disorder [12]. The intranasal route produced a statistically significant subjective desire effect versus placebo (p=0.0114) in that study. It was abandoned in later development because of post-dose blood pressure increases that were not compatible with chronic as-needed use.
- Intravenous. Used in pharmacology studies during early development, but never positioned for clinical use.
The approved label only supports the 1.75 mg subcutaneous dose, by autoinjector, into the abdomen or thigh [9]. Other routes and other formulations — including any compounded preparations marketed online — have not been evaluated by the FDA for the approved indication, and quality, purity, and identity of compounded preparations are not guaranteed.
Bottom line
The FDA-approved dosing for bremelanotide is narrow and well-defined: 1.75 mg subcutaneous, as-needed, at least 45 minutes before anticipated sexual activity, no more than once per 24 hours, and no more than 8 doses per month [9]. The dose was chosen on the basis of a Phase 2b responder analysis [15], confirmed in two Phase 3 trials [1], and supported by a 52-week extension study [2]. The frequency cap reflects the drug's cardiovascular and pigmentation profile [8] [11].
This page is editorial commentary on the published label. It is not medical advice. The decision to use bremelanotide, the dosing schedule, and the monitoring plan are clinical decisions made by a qualified prescribing clinician who has evaluated the patient in person.